Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13164341 | 0.91 | LMNA (0.53) | AKT1LMNAACHEALDH1A1VDR | |
| SCHEMBL8278972 | 0.80 | SMN1; SMN2 (0.41) | LMNACHRNA7ACHETDP1ALOX5 | |
| SCHEMBL25584028 | 0.80 | SMN1; SMN2 (0.41) | LMNACHRNA7ACHETDP1ALOX5 | |
| SCHEMBL18925491 | 0.80 | CHRNA7 (0.41) | LMNACHRNA7ACHETDP1ALDH1A1 | |
| SCHEMBL9843925 | 0.77 | MTOR (0.48) | AKT1LMNATDP1 | |
| SCHEMBL16179898 | 0.75 | TACR1 (0.36) | AKT1TDP1ALDH1A1 | |
| SCHEMBL13164322 | 0.75 | CA1 (0.48) | AKT1ACHETDP1ALDH1A1MAPT | |
| SCHEMBL14438298 | 0.75 | SMN1; SMN2 (0.51) | LMNACHRNA7ACHETDP1ALDH1A1 | |
| SCHEMBL13075027 | 0.75 | SMN1; SMN2 (0.51) | LMNACHRNA7ACHETDP1ALDH1A1 | |
| SCHEMBL23429020 | 0.73 | ACP3 (0.45) | LMNAACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636670-B2 | Catalysts, ligands and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9636670-B2 | Catalysts, ligands and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9636670-B2 | Catalysts, ligands and use thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160074852-A1 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20160074852-A1 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| EP-2986375-A2 | CATALYSTS, LIGANDS AND USE THEREOF | Isis Innovation Limited (GB) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014170642-A2 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014170642-A2 | CATALYSTS, LIGANDS AND USE THEREOF | ISIS INNOVATION LIMITED (GB) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074852-A1 | CATALYSTS, LIGANDS AND USE THEREOF | SPR, SQOR, COASY | AKT1 1393/4885LMNA 3379/4885CHRNA7 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.